Drug General Information
Drug ID	D0Z9GM
Former ID	DIB004379
Drug Name	LY-2940094
Indication	Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]		Phase 2	[524117]
Company	Eli Lilly & Co
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Nociceptin receptor	Target Info	Modulator	[551571], [551633]
KEGG Pathway	Neuroactive ligand-receptor interaction
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524117	ClinicalTrials.gov (NCT01724112) Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD). U.S. National Institutes of Health.
Ref 551571	UK Journal of Pharmaceutical and Biosciences Vol. 3(1), 12-17, 2015.
Ref 551633	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.